Spruce Biosciences (SPRB) Announces Topline Results from CAHmelia-203
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Spruce Biosciences, Inc. (SPRB) PT Lowered to $4 at Oppenheimer
March 14, 2024 9:11 AM EDTOppenheimer analyst Hartaj Singh lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $4.00 (from $7.00) while maintaining a Outperform rating.
The analyst comments "Spruce (SPRB) announced top-line results from the CAHmelia-203 and CAHptain-205 studies of tildacerfont in adult and pediatric classic CAH,... More
Spruce Biosciences (SPRB) Halted, News Pending
March 13, 2024 4:02 PM EDTSpruce Biosciences (NASDAQ: SPRB) Halted, News Pending
